Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Flupentixol/Melitracen Formulations (Deanxit)
NCT03472651Phase 1Completed
- Sponsor
- Lundbeck
- Start
- May 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of flupentixol and melitracen in major depressive disorder (MDD) and anxiety disorder, sponsored by Lundbeck. Primary endpoints: Area Under the Curve from 0 to 72 hours: flupentixol and Maximum Observed Plasma Concentration: flupentixol at 72 hours. Started May 2018; status: completed.
02
Drugs
flupentixolmelitracen
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT03472651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472651.